~~<i id='41277B15B6'><strike id='41277B15B6'><tt id='41277B15B6'><pre id='41277B15B6'></pre></tt></strike></i>~~

Home» comprehensive» explore

explore

author：comprehensive 2025-10-06 10:17:32 Page View：117

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： An interview with Robert F. Kennedy Jr. on vaccines
Next article： Trump demands the U.S. pay no more for drugs than other countries … again

explore

What does generative AI mean for health care? We asked experts

MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

A neonatal nurse in a British hospital has been found guilty of killing 7 babies

ThiscourtartistdrawingbyElizabethCookfromAug.10,2023showsofnurseLucyLetbyatManchesterCrownCourtinMan

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Tocagen's brain cancer gene therapy trial continues. Investors worry

MichelleMonje/StanfordUniversity/NIHTocagen(TOCA)saidTuesdaythataPhase3clinicaltrialinvolvinganovelg